The Work That Makes a Partner

Merida Biosciences / Eli Lilly

Autoimmune medicine often begins with an ugly bargain: calm the disease by quieting parts of the immune system a patient still needs.

Merida Biosciences was built around the harder version of that problem. Find the antibodies driving a specific disease, remove them, suppress the B cells producing them, and leave protective immunity doing its job. Eli Lilly and Company has decided that proposition is worth buying before Merida’s lead program leaves Phase 1.

Lilly agreed to acquire Merida for up to $2.875B in cash, including an undisclosed upfront payment and contingent milestones. The deal is expected to close in Q4 2026, subject to conditions and regulatory approvals. That “up to” is doing real work: part of the maximum price remains attached to proof the science still has to produce.

Founder and CSO Dario Gutierrez helped seed Merida at Third Rock Ventures in 2022. The company launched publicly in April 2025 with a $121M Series A co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock. CEO Adam Townsend joined as Merida moved from platform construction into clinical execution.

The first test is MER511. The Phase 1 NEXUS study is evaluating the biologic in adults with Graves’ disease, where pathogenic antibodies continuously stimulate the thyroid. Lilly says initial data showed robust antibody reductions with a favorable initial safety profile. The findings are preliminary and company-reported, but they gave Lilly an early look at the biology behaving in people.

Merida’s engineered Fc biotherapeutics are designed to bind selected pathogenic antibodies, direct them toward degradation in liver cells, and inhibit their B-cell sources. Programs extend the platform into IgE-mediated allergic diseases and primary membranous nephropathy.

This is more than a Graves’ disease asset purchase. Lilly is acquiring a method for separating the part of immunity causing harm from the parts patients need preserved. If that selectivity survives larger trials, the platform could travel across autoimmune and allergic conditions that still lean on broad suppression.

Merida gets Lilly’s clinical-development scale and capital. Lilly gets a young platform with one early human signal and several programs behind it. The transaction settles none of the scientific questions. It changes who has the resources to keep asking them across more diseases and larger studies.

The next chapter sits inside “selective.” Merida has shown enough for Lilly to buy the laboratory, the team, and the possibility. Patients will decide the value later, one preserved piece of immune function at a time.

Diffraqtion

Most cameras lose the argument before the software gets a vote.

Light reaches the lens carrying more than brightness. It also carries structure: how many objects are there, which one moved, and what separates distant points that ordinary optics blur together. Conventional cameras discard much of that information, then ask software to make a confident guess from what remains.

Diffraqtion is building around a different order of operations. The Somerville spinout uses passive photonic hardware to sort incoming light by shape, then a proprietary model layer turns that signature into an answer. No qubits. No cryogenics. The quantum part is quantum estimation theory applied to what light can reveal.

That distinction attracted 2 investors that rarely appear merely to admire elegant physics. Lockheed Martin Ventures and Presidio Ventures, the venture arm of Sumitomo Corporation, made strategic investments that cap Diffraqtion's pre-seed and take total company-reported funding above $10M. The incremental amount was not disclosed.

January's first close combined equity with non-dilutive DARPA support, so the $10M total is not one $10M equity round.

The founding team fits the handoff ahead. CEO Johannes Galatsanos brings AI and operating experience. CTO Christine Wang has spent more than 20 years in photonics R&D. Chief Scientific Advisor Saikat Guha led the underlying DARPA and NASA work. Peter Kazlas joined as Head of Engineering after 25 years taking optics into production.

Diffraqtion reports on-sky demonstrations that distinguished closely spaced objects. Its DARPA Direct-to-Phase-II SBIR has entered a second option period. NASA selected the company for an orbital-debris-tracking SBIR Phase I and named it the $100,000 Space to Soil Challenge winner.

The performance envelope remains company-reported. Simulations indicate features up to 20 times smaller can be resolved and targets classified orders of magnitude faster than conventional pipelines. The capital is meant to carry that advantage into a first fielded camera and hosted-payload flight heritage.

Defense, space, and industrial operators do not buy prettier pixels. They buy earlier recognition, smaller payloads, lower compute burdens, and enough confidence to act while the object is still in view.

Diffraqtion has spent a decade asking how much more information can be pulled from light. Its strategic backers are financing the harder answer: how much of that information can survive the trip from physics into a deployed mission.

Fisher Management Partners / Trinity Hunt

A consulting firm can sell strategy from a conference room. The harder promise is staying beside the client when the operating work starts pushing back.

That promise sits underneath Trinity Hunt Partners' investment in Fisher Management Partners. The Columbus firm will become the foundational company in a new value-creation services platform, with founder and Managing Partner Todd Fisher and Fisher's existing partners continuing to lead. Transaction terms were not disclosed.

Fisher works across business strategy, sales and marketing, operations and supply chain, finance, people, and technology. Six practices can look like a menu until a middle-market company discovers that its growth problem refuses to stay in one department. One decision can change sales, expose bad data, trigger technology work, and reach the people expected to make the plan real.

Fisher's answer is a senior-level Working Partner who stays close to that chain. The firm sells the handoff from strategy into action, where recommendations meet budgets, incentives, systems, and Monday morning.

Trinity Hunt and Fisher are already looking for consulting firms with complementary capabilities, geographies, or industry specializations. Expansion is part of the thesis from day one.

George Morgan, a Trinity Hunt Partner and investment-committee member, framed the opportunity around hands-on execution. Trinity Hunt brings more than $2B under management and a services playbook that includes organic growth and acquisitions.

Dinsmore, Fisher's adviser, described a sale involving acquisition structure and a complex reorganization. No reviewed source disclosed the stake, purchase price, valuation, or detailed terms.

A boutique earns trust because senior people remain visible. A platform earns scale by making more expertise available. Every firm added to this one will put those strengths in the same room.

Middle-market clients rarely need one more deck. They need people who can trace a problem across functions, stay through the ugly handoffs, and help the operating team own the result. The next additions will show whether Fisher's Working Partner proximity can carry a broader consulting business, one integration and one client decision at a time.

Be Clinical

Hemangi Dhir did something founders are trained to postpone: she killed the brand that got her into the room.

Botnal had customers and products. It kept showing Hemangi Dhir the same signal. The people returning most often were dealing with ageing concerns, and they were not looking for another pretty bottle with a familiar ingredient list. They wanted evidence that the formula had been built for the skin they actually live in.

So Hemangi Dhir shut Botnal down and rebuilt it as Be Clinical, a skin-longevity company organized around a narrower promise and a more expensive operating choice.

Now Be Clinical has raised ₹21 Cr, about $2.2M, in a seed extension led by Sauce. Existing investor V3 Ventures participated, alongside Mokobara founders Sangeet Agrawal and Navin Parwal, Reckitt executive Arjun Purkayastha, and Shaunak Chirayu Amin.

The transaction brings Be Clinical's announced financing to ₹29 Cr across three reported rounds: ₹2 Cr, ₹6 Cr, and now ₹21 Cr. No valuation or ownership terms were disclosed.

That capital is going behind the packaging. Be Clinical says it handles formulation and manufacturing in-house, conducts clinical testing before launch, and registers trials with India's Clinical Trials Registry. Its current products target concerns including firmness, fine lines, the eye area, the neck, hands, and menopausal skin.

The company reported 1.2 lakh orders since its May 2025 launch. V3 Ventures said sales grew 5x in nine months while the business remained profitable. Those are company and investor claims, not audited results.

Be Clinical will use the round to deepen R&D and clinical testing, expand manufacturing, build products across skin, body, and haircare, hire, and enter new markets.

There is a useful business lesson inside that list. Beauty brands can rent manufacturing, buy distribution, and turn customer acquisition into a polished spreadsheet. A clinical claim is less portable. It has to survive formulation changes, batch production, testing, customer use, and the second order that either arrives or does not.

Hemangi Dhir chose to destroy some brand equity before building the operating system underneath the next promise. Sauce and V3 Ventures are financing the part after that decision, when a focused anti-ageing thesis has to become a wider company without letting “clinical” dissolve into category wallpaper.

The next chapter will be written inside that handoff: more products, more batches, more customers, and the same word waiting to be earned each time.

Reframe Systems

Housing is the rare factory problem where every finished product arrives with its own zoning board, weather pattern, street, and buyer. Repetition makes manufacturing cheaper. Local reality keeps asking the house to be different.

That contradiction is the business behind Reframe Systems' additional $40M in equity financing. Energy Impact Partners led the Series A extension, with Counterpart Ventures, E12 Ventures, Global Brain, Thin Line Capital, UP Partners, and LACI Impact Fund joining. Eclipse, VoLo Earth, Cubit Capital, RA Capital Management's Planetary Health team, MassMutual Catalyst, and Nor'easter returned.

Co-founder and CEO Vikas Enti helped integrate Kiva robots across Amazon's warehouses. Felipe Polido and Aaron Small joined him from Amazon Robotics. The three helped deploy more than 500,000 robots. Housing handed them a nastier problem: the boxes are now rooms, the destinations are permanent, and every local constraint comes with a permit.

Reframe's answer is not one giant factory making one rigid home. Regional microfactories use software, vision-guided robots, and digital work instructions to produce site-customized housing. The system repeats while homes respond to climate, code, site, and neighborhood form.

The new capital moves that thesis into a larger test. FAB1 in Billerica, Massachusetts, is designed to produce up to 500 multifamily units or 250 single-family homes annually with less than $5M of equipment. Reframe says operations will begin October 5 after commissioning in less than 70 days.

Those are design targets, not current throughput. The operating evidence is earlier but real: Reframe reports 10 completed homes, 8 already occupied, and another 114 units expected over the next year. The Information reports $15M in current bookings. Projects in Devens, Roxbury, Thornton, and Altadena put very different local demands through the same production logic.

Factory-built housing has collected expensive cautionary tales. Automation can frame a wall. It cannot guarantee permits, site work, factory utilization, logistics, or a customer ready with the line. Reframe is keeping equipment light while asking software and regional deployment to carry more of the learning.

The $40M gives the founders room to prove that a factory can absorb local variation. FAB1 now has to turn that industrial architecture into occupied homes, predictable schedules, and economics developers will trust across the next city line.

Easy Aerial

An aircraft becomes expensive the moment its usefulness depends on how long the battery lasts. Over a perimeter, convoy, vessel, or critical site, the operator is not buying a flight. The operator is buying reliable awareness.

That is the trade behind Easy Aerial Inc.'s $20M Series B. Insight Partners, Entrée Capital, and private U.S. investors participated in the round, which will expand production, international defense programs, global operations, and the company's autonomous aerial technology.

Easy Aerial builds tethered and free-flight drone-in-a-box systems for ISR, force protection, perimeter security, emergency response, and critical infrastructure. The tether looks like a restriction until the mission asks the aircraft to stay up. Then it becomes power, a secure data path, and one less battery clock controlling the operation.

CEO Shahar Abuhazira is scaling the company around that reality. Founder and CPO Ivan Stamatovski and the team have spent years moving the product from autonomous monitoring into rugged defense systems designed for remote deployment, vehicle and vessel integration, and persistent sensing.

The company says it has delivered hundreds of systems worldwide. It also recently reported a 118-system European program with Height Technologies for an unnamed NATO-aligned defense customer, with assembly underway in the Netherlands. Those are company-reported deployment signals, not disclosed revenue, but they explain why the new money is aimed at manufacturing and programs rather than another demonstration.

Before this round, Easy Aerial disclosed $4.75M in seed financing and a $6.15M Series A. The Series B brings disclosed equity funding to $30.9M. No lead investor, valuation, ownership terms, or private participants were identified.

Insight Managing Director and Easy Aerial board member Mike Hayes framed the investment around persistent, reliable aerial intelligence without operational complexity. That is a manufacturing promise as much as a product claim.

Defense technology can get hypnotized by movement. Faster aircraft, longer range, more autonomy, more software. Easy Aerial is building around a less cinematic question: can the system remain useful, powered, connected, and available while the people below it keep working?

The $20M now has to turn demand into repeatable production across borders. A tether can keep an aircraft in the air. Manufacturing, integration, and field support will decide whether that aircraft becomes infrastructure.

EIT Pharma

A biotech company can run out of road before its molecule does.

That is the starting point for EIT Pharma, Inc., which closed an oversubscribed $35M Series A led by Propel Bio Partners, with Good Ventures, Arrowtown, and others participating.

The round is financing something less cinematic than discovery: the operating company around a late-stage asset.

EIT Pharma acquired the antiviral lonafarnib program from Eiger BioPharmaceuticals in a 2024 bankruptcy sale. SEC filings put its price at $5.2M. The scientific work survived the corporate collapse. A new team inherited the obligation to carry it forward.

That team now has a regulatory application under review. EIT Pharma announced on August 11 that the FDA accepted its NDA for lonafarnib in chronic hepatitis D, a serious liver disease in people who also have hepatitis B. Acceptance starts the review; it is not approval, and lonafarnib remains investigational for this indication.

The application is supported by D-LIVR, a completed Phase 3 study registered as NCT03719313. EIT Pharma describes it as the largest chronic-hepatitis-D trial to date, with more than 400 participants across 21 countries. WHO estimates nearly 12M people globally live with hepatitis D and calls chronic HDV the most severe form of chronic viral hepatitis.

The financing puts money behind the handoffs that determine whether data becomes medicine: FDA review responses, manufacturing readiness, commercial preparation subject to approval, and continued work across EIT Pharma's infectious-disease pipeline.

The investor relationship deserves daylight. Leen Kawas is both EIT Pharma's CEO and Propel Bio Partners' co-founder and Managing General Partner. Xue Hua is EIT Pharma's Chief Development Officer and a Propel Managing Partner. This may concentrate domain knowledge and speed decisions, while making disclosure and execution discipline especially important.

Biotech likes to celebrate invention because invention photographs well. Asset rescue is messier. It asks whether prior clinical work can retain value after the original company breaks, whether a new organization can rebuild regulatory continuity, and whether capital will stay patient through manufacturing and review.

EIT Pharma has bought itself room to answer those questions around lonafarnib. The molecule carried years of work into the room. The $35M now has to build the company capable of carrying that work through the next door.

Kingsview Partners / FTV Capital

The independent advisor still needs an institution. It just has to be one the advisor chose.

Clients may see one trusted person across the desk. Behind that relationship sit compliance, custody, technology, portfolios, insurance, onboarding, marketing, and daily operations. Independence does not erase the machinery. It changes who builds it and whether the advisor feels supported without feeling managed.

That is the business inside Kingsview Partners' new growth investment from FTV Capital.

Kingsview is an integrated wealth-management platform and independent RIA. It says it supports 100+ advisors across 70+ offices in 23 states and 15,000+ households. Its model combines planning and investment management with asset management, insurance, technology, compliance, operations, marketing, and transition support.

The amount and financial terms were not disclosed. The transaction is expected to close in Q4 2026, subject to customary closing conditions and regulatory filings. Kingsview's management team will continue to lead the company and retain significant ownership.

Founder and CEO Josh Lewis built the platform around growth-minded advisors who want autonomy without rebuilding an entire financial institution behind their practice. The joint announcement reports more than $10B in AUM, average annual growth above 35% over the last three years, and 97% average advisor retention over the same period. Those are company-reported figures, but together they explain what FTV is underwriting: not a loose collection of advisory offices, but an operating system advisors keep choosing to stay on.

FTV Partners Kyle Griswold and Mike Vostrizansky, along with Vice President Brandon Spierto, led the transaction and are expected to join Kingsview's board after closing. FTV also brings its Propel operating team and 600+ executive network to help expand Kingsview's advisor base, technology, operations, products, and client experience.

The competitive tension is delicate. Every new advisor creates scale for the platform, but the platform earns that advisor by preserving the independence that made the move attractive. Centralize too little and the economics get heavy. Centralize too much and the promise starts sounding like the institution the advisor left.

Kingsview is financing the narrow ground between those outcomes. The next stretch will show whether a larger operating layer can stay nearly invisible to the advisor while becoming more useful behind the client relationship.

Molten Salt Solutions

Fusion’s fuel cycle begins in a chemistry plant the reactor renderings usually crop out.

The plasma can work. The reactor design can mature. None of that creates the enriched lithium those systems expect to consume. Molten Salt Solutions is financing the less glamorous handoff from breakthrough to material that arrives on specification, on schedule, and in enough volume to matter.

The Santa Fe company closed an oversubscribed $7M Seed round led by Dolby Family Ventures. Vanedge Capital, Alumni Ventures, Gaingels, True Ventures, and Future Ventures participated. It follows a $3M pre-seed and more than $5M in grants, putting disclosed equity at $10M without pretending grant support is venture capital.

Founder and CEO John Elling built Molten Salt Solutions around an awkward split inside one element. Fusion systems need enriched lithium-6 to breed tritium. Certain advanced fission molten-salt reactors need lithium-7 because it absorbs fewer neutrons and limits unwanted tritium formation. Two reactor markets have different isotope requirements and the same thin supplier base.

Molten Salt Solutions uses high-speed counter-current chromatography and liquid-liquid solvent exchange to separate those isotopes. The company says its platform is 100X more efficient than legacy methods. That remains company-reported, but a New Mexico program with Los Alamos advanced the method to TRL 4 and documented laboratory validation.

The $7M is meant to move the company toward pilot-scale production, expand technical and operations teams, and fulfill customer agreements. Type One Energy and Gauss Fusion signed nonbinding strategic sales agreements. Fissionaire announced a separate commercial agreement for lithium-7. That is qualified evidence of demand, not proof that production is solved.

Deep-tech capital gets framed around invention. Customers eventually buy repeatability: purity they can qualify, throughput they can plan around, delivery windows that fit reactor programs, and a supplier that still exists when testing becomes deployment.

Dolby Family Ventures and the participating investors are financing the handoff from promising chemistry to operating discipline. If Molten Salt Solutions makes it, the company will sit upstream of two nuclear categories whose timelines depend on materials most public conversations barely mention.

The reactor may own the headline. The isotope plant has to be ready before that headline plugs into the grid.

JetZero

An airplane can still live mostly in engineering files while its financing already has to behave like a factory.

JetZero has closed a senior secured term loan facility of up to $100M led by Pinegrove Venture Partners and Silicon Valley Bank. Proceeds are intended for technology maturation, Jet1 demonstrator manufacturing, tooling, Greensboro manufacturing and test facilities, and U.S. working capital.

That is a different financial job from the approximately $175M Series B JetZero announced in January. Equity backed the thesis. Credit arrives as it turns into equipment, buildings, schedules, and measurable milestones.

Tom O'Leary, CEO and co-founder, and co-founder Mark Page built JetZero around a shape commercial aviation has studied for decades but has never put into passenger service at this scale. The Z4 targets roughly 250 passengers and up to 5,000 nautical miles. JetZero says the all-wing configuration can cut fuel burn and emissions by up to 50% against comparable tube-and-wing aircraft.

The aerodynamic promise is easy to admire. The industrial handoff is harder. Jet1, the full-scale demonstrator being built with Scaled Composites, was 40% complete as of June 2026, with first flight scheduled for Q4 2027. Greensboro's planned campus covers 8M square feet on more than 600 acres, with 14,500 jobs projected across 10 years.

Those numbers create obligations. A demonstrator must become flight data. Tooling must become repeatable production. A campus must organize suppliers, labor, certification, quality, and delivery. Airline interest must survive the distance between a conditional agreement and an aircraft entering service.

CFO and Treasurer Sergey Kulyagin called the new lenders investors and stakeholders in JetZero's funding roadmap. Pinegrove partner Craig Caukin said the facility was structured around real program milestones and could expand. “Up to $100M” is capacity, not proof that every dollar was drawn at closing.

JetZero is also exploring up to $3B in potential EXIM support for Greensboro, but that July letter of interest is not a financing commitment.

The lender decision puts a new clock beside the engineering clock. Pinegrove and SVB are financing the passage from an aircraft people can believe in to a program that must keep earning the next draw through physical progress. The next signal will come from the handoff between Mojave, Greensboro, regulators, suppliers, and the first full-scale flight.

De¹

A trading agent can ace every backtest and still discover, one fill too late, that the market was grading a different exam.

Historical data can show what happened. It cannot fully show what would have happened after this particular agent placed this particular order. The order changes available liquidity, price, slippage, and the next decision. The moment an agent begins moving capital, prediction becomes participation.

That consequence loop sits at the center of De¹, which has received a $500K investment from YZi Labs through EASY Residency Season 4.

De¹ is building what it calls a Financial World Model for autonomous on-chain trading. The system brings market simulation, financial reasoning, on-chain execution, and verifiable feedback into one training and operating loop. The company reports connectivity to more than 1,000 liquidity sources across more than 40 chains.

The ambition is larger than producing another model that can identify a trade. De¹ is trying to give financial agents a place to learn how a decision behaves after it becomes an order, how the market responds to that order, and whether the resulting outcome deserves to influence the next action.

De¹ places execution inside the learning problem. Its architecture is designed to connect simulated environments with live market outcomes, creating feedback that can be verified on-chain rather than inferred only from a model's explanation. If that loop works, the useful artifact is not merely a smarter prediction. It is a record of whether the agent behaved intelligently when the market pushed back.

YZi Labs selected De¹ as one of 24 companies in its fourth EASY Residency cohort. YZi says every company in the cohort received $500K. The investment is best understood as strategic backing inside that program; no valuation, ownership percentage, or priced-round label was disclosed.

There is still a meaningful distance between an architecture and dependable autonomous finance. De¹ has to show that its simulations remain relevant as conditions change, that execution feedback improves behavior instead of amplifying noise, and that verifiability can make agents more accountable rather than simply more active.

The market will eventually grade the system with harder questions than a benchmark can ask. When the agent's own trade becomes part of the environment, intelligence is no longer what it predicted. It is what survived contact with the fill.

Atorie

A luxury label does more than identify who designed the bag. It carries the trust that lets a shopper inspect the leather, stitching, and construction, then accept a price several floors above the factory cost.

Atorie is betting that some of that trust can move toward the people making the product.

The Los Angeles marketplace raised a $9.5M Seed round with a16z speedrun, Night Capital, and Jeremy Liew of Lightspeed participating. No lead investor or valuation was disclosed. Co-founder and CEO Redouane Ramdani built the company with co-founder and CTO Luis Angulo.

Factories traditionally received a brand’s design and large order, then carried much of the production risk. Ramdani told TechCrunch that leading manufacturers are increasingly developing products themselves and producing in smaller batches.

That changes who owns the useful information. A factory with design talent and live demand signals can decide what to make, when to make it, and which customer relationship is worth keeping.

Atorie is building the operating layer around that shift, selling fashion from ateliers directly to consumers. The company says many products use the same kinds of materials and, in some cases, the same factories associated with established luxury manufacturing. That is Atorie’s claim, but the commercial question is real: will a shopper pay for workmanship when the heritage logo is no longer doing the selling?

AI sits on both sides of the answer. Atorie says its models analyze trends, estimate demand, and anticipate material shortages before production. Its shopping assistant helps consumers search and style outfits, while referrals from ChatGPT and Claude are rising.

The company reported about $5M in 2025 sales, an expected annualized run rate above $55M in 2026, and relationships with 40+ factories. Those are company figures, and run rate is not completed annual revenue. The capital will support logistics, production, AI tools, and an in-house line.

Now Atorie has to make dozens of ateliers feel like one dependable storefront while protecting quality, delivery, returns, and inventory discipline. Software can improve the forecast. The customer still judges the seam, the shipping box, and whether the second order feels as certain as the first.

If that reliability holds, factories can own more design, demand knowledge, and margin without becoming global brands from scratch. Atorie will carry the customer relationship across that distance.

Retro / Lone Palm Labs

The camera roll is full. The group chat still has to ask everyone to send the good ones.

That small inconvenience is the crack Retro is trying to widen into a company. Social media became astonishingly good at finding content from strangers and oddly clumsy at helping people keep up with the friends whose photos already matter.

Nathan Sharp and Ryan Olson know that machinery from the inside. The Lone Palm Labs co-founders worked at Instagram, where Sharp helped launch Stories and Olson served as an iOS tech lead before becoming a director of engineering. They left with a smaller ambition for Retro: build the best place to catch up with friends and family.

The financing behind that idea is now public. Lone Palm Labs sold $21,104,978 in Series A equity, according to a Form D filed August 19. The offering closed December 31, 2025, months before the filing surfaced. TechCrunch reported the round August 28 and later added company confirmation.

Field Ventures, associated with Dylan Field, and Thrive Capital led the Series A, with Positive Sum and several new and existing angels participating, TechCrunch reported.

Retro organizes sharing around weekly photo cards, collaborative journals, recaps, and a rewind through old memories. There is no advertising model feeding on the next scroll. Subscriptions unlock richer comments, more styles, unlimited history, and special icons.

That choice sounds peaceful because it is. It is also commercially unforgiving.

An advertising network can monetize attention even when most people watch and very few contribute. Retro needs whole friend groups to keep showing up—and enough members to pay.

The early numbers offer a reason to keep testing. Appfigures estimates cited by TechCrunch put Retro near 7M downloads, with in-app spending up more than 460% over the past 180 days. The company has not disclosed active users, subscribers, revenue, or retention.

That uncertainty is part of the interesting work. Consumer social spent years teaching investors to prize reach, feed velocity, and advertising inventory. Retro is asking whether a smaller graph can become more valuable precisely because everybody in it has a reason to care.

The Series A gives Sharp, Olson, and their small team more room to find out. Every new friend group will bring the same quiet negotiation with it: who shares, who returns, and whether a place built for people you know can stay worth paying for as more of them arrive.

Saviynt / Carrick Capital Partners

A continuation vehicle gives investors a choice the original fund eventually cannot: take liquidity now or keep traveling with the asset.

Carrick Capital Partners just built that choice around Saviynt. The firm closed an oversubscribed single-asset vehicle with approximately $600M in commitments, led by Coller Capital with HSBC Asset Management as co-lead, and committed another $255M to the identity-security company.

The accounting matters. Approximately $600M belongs to the vehicle. The $255M is the new investment in Saviynt, made as part of the final close of its $700M Series B and used in part to fund a tender offer for employees. Existing Carrick LPs could roll their equity or take liquidity at a sponsor-reported 11x gross and 10x net multiple on the firm's initial investment.

One transaction now gives original investors a realization, employees a tender path, Carrick's GPs more exposure, and Saviynt more capital to build.

Carrick led Saviynt's $35M Series A and says it remained the only institutional investor until the Series B. Chris Wenner and the team are making Carrick's largest investment after Saviynt reported more than $300M ARR, 2026 bookings growth above 80%, and 96% customer retention.

Sachin K Nayyar and the Saviynt team built identity governance for employees, contractors, applications, and service accounts. AI agents change the tempo. They choose tools, call APIs, touch data, and act across systems at machine speed. Last quarter's access review cannot explain what an agent may do in the next second.

Saviynt launched Zuma to discover AI agents and non-human identities, assign ownership, map access, authorize actions at runtime, and govern lifecycles. NIST is asking the same category-level questions about agent identities, credentials, delegation, auditing, and accountability. The buyer must govern what an authorized machine may decide after it gets inside. Enterprise AI is turning identity from a compliance layer into operating authority.

The capital is expected to support Identity Cloud and Zuma development plus deeper integrations. The announcement does not disclose the split between primary capital and employee liquidity, a 2026 vehicle valuation, or Zuma-specific revenue.

Carrick has chosen more time inside this transition. Saviynt now has to make accountability fast enough for the software actors it governs and practical enough for enterprises to place it where permission turns into action.